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ABSTRACT 
Background and Objective 
Tuberculosis epidemic has reached astronomic and emergency proportions, particularly in Southern Africa, 
despite efforts by key stakeholders in implementing necessary control strategies. The diagnosis of TB is still 
based on smear microscopy in many parts of Africa while the emergence of drug-resistant TB is increasing. We 
are reporting on the outcomes of samples received in a TB reference laboratory in Swaziland and results from 
an assessment of non-clinical staff’s knowledge, attitudes and beliefs towards TB and IPC related issues in public 
health facilities in South Africa. 
 
Methods 
A self-administered close-ended questionnaire was used to collect cross-sectional data among non-clinical staff 
in 5 public hospitals in KwaZulu-Natal between April 2011 and November 2011. In a TB reference laboratory in 
Swaziland, using   MGIT automated instrument, sputum samples were screened for TB from June 2011 to 
December 2011. Positive cultures were confirmed as MTB complex using ZN smears and TB Ag MPT64 and then, 
the drug susceptibility testing was done on RIF, INH, Streptomycin and Ethambutol using the 1% proportion 
method. 
 
Results 
Of the 79 non-clinical staff, 67.4% were of the opinion that a surgical face mask protects the wearer from 
contracting TB while 44.3% did not understand rational behind triage and fast-tracking of patients in TB control 
program. Of great concern, 25% of non-clinical respondents perceived no risk of contracting TB in hospital 
environment and believed that TB was caused by drinking and smoking. Whilst 10% of these respondents 
desperately felt that there is no means of protection against TB; they also expressed that there is no need to 
implement a screening program for staff.  
Samples were obtained from 6163 patients of which 22.3% were culture positive and of these culture positives, 
90% were MTB complex and 10% were NTM.  Among patients diagnosed with TB, 52% were smear positive and 
48% were smear negative. Sixty-six percent of these cases were MDR follow up cases with 3.4% relapse cases, 
and 4.5% failure to convert.  
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Conclusion 
While knowledge of staff about TB Infection Control is still very low, DR-TB cases are increasing. The study 
underlines the need to prevent DR-TB by bridging knowledge gaps among HCWs and necessity to improve 
laboratory capacity to support TB control efforts. 
 
 
Keywords: DR-Tuberculosis, Infection Prevention and Control, Strengthening laboratory Capacity, Southern 
Africa.   
 
INTRODUCTION 
TB has become epidemic in the setting of a generalized HIV epidemic in southern Africa, and 
HIV infection has had a strong influence on the increased numbers of drug-resistant TB cases 
in the region. (WHO 2008) Drug-resistant TB imposes a tremendous health burden 
throughout southern Africa. Thus, it has become imperative to understand the dynamics of 
the TB epidemic in Southern Africa to be able to prevent the potential existence for the 
explosive spread of Drug-resistant TB. 
One in four young adults in South Africa is infected with HIV and of these, up to two thirds 
may also be infected with TB. Conversely, between 60% and 80% of new TB cases in South 
Africa also have HIV infection yet HIV fuels TB infection due to weakened immune system [1]. 
Drug-resistant TB in the context of southern Africa's HIV epidemic raises many important 
clinical issues, including the lack of diagnostic capacity to detect TB and perform drug 
susceptibility testing, with many patients dying before the extent of their drug resistance can 
be assessed; lack of  measure infection control; TB infections that test negative on sputum 
smears and extra-pulmonary TB; availability of treatments, including second-line drugs; drug 
toxicity; treatment with antiretrovirals and the challenges of managing multiple medications 
and their interactions; and immune reconstitution inflammatory syndrome (IRIS) [2]. 
For every patient who is diagnosed with and treated for MDR TB in southern Africa, it is likely 
that several more are diagnosed and not treated. Further, an even larger number of those 
infected with MDR TB are never diagnosed because diagnostic capabilities are inadequate or 
because these people die without ever having been seen and diagnosed through the health 
care system. It has been noted that in South Africa alone, defaulter rate of those on second- 
line TB treatment is at 20% with no difference between HIV positive and HIV negative TB 
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patients (WHO 2008). It was also noted that patients coinfected with HIV were three times 
more likely to die than patients without HIV [3]. 
Muti-drug resistant TB (MDR-TB) is TB which cannot be treated by the usual first line anti-TB 
drugs. TB can usually be treated very effectively with a 6month course of four first line anti-
TB drugs (Isoniazid, ethambutol, rifampicin). These drugs are safe, inexpensive and effective. 
However, if patients are incorrectly treated or do not complete their full course, drug resistant 
strains of Mycobacterium tuberculosis can arise. Multidrug-resistant Tb (MDR-TB) Is defined 
as TB resistant to the two most potent first line anti-TBdrugs (isoniazid and rifampicin). Once 
MDR-TB emerges, first-line anti-TB drugs will no longer work and second line drugs 
(Fluoroquinolones, kanamycin, capreomycin, amikacin) have to be used [4]. 
Second line anti-TB drugs require a lengthy (up to 24 months) treatment and are 100 times 
more expensive and patients experience more severe and unpleasant side-effects than with 
the first-line drugs. The drugs are not readily available yet it is vital that MDR-TB treatment is 
used correctly and not interrupted to prevent additional resistance developing leading to 
Extensively drug resistance TB (XDR). 
MDR-TB spreads to vulnerable individuals in the same way as drug-susceptible TB, and 
infected persons have the same risks of developing active disease in the presence of HIV as 
those infected with a drug-susceptible TB. We cannot talk about MDR-TB and leave XDR-TB 
as this develops due to mismanagement or misuse of the MDR-TB drugs which become 
ineffective. Because XDR-TB strains have developed resistance to most of the first-line and 
second-line drugs available to treat TB, and is potentially untreatable. XDR is defined as 
Mycobacterium tuberculosis which multi-drug resistant, with additional resistance to a 
fluoroquinolone and one or more of the injectable drugs (kanamycin, amikacin, capreomycin), 
which are second line drugs of choice [5]. 
XDR-TB was first reported in Kwazulu Natal in 2006 [1] were in a group of 53 XDR patients, all 
but one died within an average of 25days from the point when drug-resistant TB was first 
suspected. Forty four of the 53 patients were HIV positive. The case scenario therefore 
becomes the same in other Southern African countries with high HIV rates like Swaziland. 
High TB rates of infection due mostly to poverty. Swaziland is surrounded by South Africa and 
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us it is affected also by the South African TB/HIV statistics as there is more interaction of the 
populations. This is the same case scenario with Lesotho which also has a high rate of HIV/TB 
infections [6, 7, 8]. 
This study looks at the data collected in Swaziland TB National reference laboratory   and the 
attitude of non-nursing staff on ways of controlling the spread of TB in Kwazulu natal South 
Africa. 
 
 
OBJECTIVES 
To assess the attitude, knowledge and beliefs of the non-clinical staff towards TB AND IPC 
related issues in Kwazulu natal. Analysis of the TB culture results from Swaziland reference 
laboratory. 
 
MATERIALS AND METHOD  
Objective 1, data was collected using self-administered close ended questionnaire between 
April2011-Nov 2011 in Kwazulu Natal South Africa. 
Objective 2, sputum samples received in The National TB reference laboratory Swaziland were 
cultured using MGIT automated instrument using 4% NAOH concentration method (CDC). 
• Positive cultures were confirmed as MTB complex using ZN smears and TB Ag MPT 64 
identification test. 
• Drug susceptibility testing was done on RIF, INH, Streptomycin and ethambitol using 
1%prportion method. 
• Resistant cultures were sent to MRC Laboratory South Africa for second line drug 
susceptibility testing. 
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RESULT 
a) Overall summary of culture results 
Table no. 1 
CULTURE RESULTS 
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
0.08% 0.80%
4.50%
1.60%
9.40%
0.40%
66%
0.42% 0.06%
3.40%
8.70%
3.60%
0.02%
 
 
b) Break down of culture positive results 
Table no. 2 
Culture results and outcomes
Sputum Samples
from
6163
Culture positives
22.3%
MTB Complex
90%
NTM
10%
Smear positive
52%
Smear Negative
48%
MDR follow ups
60%
Relapse cases
3.4%
Failure to convert
4.5%
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c) Survey results 
Table no. 3 
Non clinical staff attitude
79 closed questionnaires
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
For surgical mask See no rationale Perceived no risk No means of protection
67.40%
44.30%
25%
10%
 
 
 
CONCLUSION 
Dr.  Mario Raviglione, Director of the WHO STOP TB Department, said that the fight against 
TB and XDR-TB is now the responsibility of a wide range of individuals and organizations. Most 
importantly, TB control programmes need to function effectively and patients with TB need 
access to proper drugs and should adhere to treatment regimens according to WHO 
guidelines (WHO 2008). 
It is also crucial to administer second line TB drugs under very tightly controlled conditions so 
that they retain their potency. 
The cultural values and stereotypic issues around TB, MDR, XDR should also be addressed 
through proper information dissemination to the affected populations and should be 
considered as the paramount factor in understanding an individual will complete treatment 
or not. 
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